Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 742, Issue 1-2, 2012, Pages 92-95

  He, Zhiming ^a   Kosinska, Wieslawa ^a   Zhao, Zhong Lin ^a   Wu, Xue Ru ^b,c   Guttenplan, Joseph B ^a,b  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Bladder cancer; Carcinogenesis; Mutagenesis; N nitroso n butyl n hydroxy n butylnitrosamine; Urothelial carcinoma; Urothelium

Indexed keywords

DRINKING WATER; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER; BLADDER CANCER; CARCINOGENESIS; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FORESTOMACH; GENE MUTATION; KIDNEY; MALE; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; URETER;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; ENVIRONMENTAL POLLUTANTS; FEMALE; MALE; MICE; MICE, INBRED C57BL; MUTAGENS; ORGAN SPECIFICITY; RATS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

MUS; NICOTIANA TABACUM; RATTUS;

EID: 84856112249     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2011.11.015     Document Type: Article

References (28)

1. Lotan Y., Kamat A.M., Porter M.P., Robinson V.L., Shore N., Jewett M., Schelhammer P.F., deVere White R., Quale D., Lee C.T. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer 2009, 115:4096-4103.
2. A.C. Society Cancer Facts and Figures, American Cancer Society, Atlanta, GA, 2011.
3. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003, 21:1315-1330.
4. Janzowski C., Jacob D., Henn I., Zankl H., Poole-Zobel B.L., Eisenbrand G. Investigations on organ-specific metabolism and genotoxic effects of the urinary bladder carcinogen N-nitrosobutyl-3-carboxypropylamine (BCPN) and its analogs N-nitrosodibutylamine (NDBA) and N-nitrosobutyl-4-hydroxybutylamine (4-OH-NDBA). Toxicology 1989, 59:195-209.
5. Suzuki E., Anjo T., Aoki J., Okada M. Species variations in the metabolism of N-butyl-N-(4-hydroxybutyl) nitrosamine and related compounds in relation to urinary bladder carcinogenesis. Gann 1983, 74:60-68.
6. Ames B.N., Gold L.S., Willett W.C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. U.S.A. 2010, 92:5258-5265.
7. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
8. Davidson J.F., Guo H.H., Loeb L.A. Endogenous mutagenesis and cancer. Mutat. Res. 2002, 509:17-21.
9. Lambert I.B., Singer T.M., Boucher S.E., Douglas G.R. Detailed review of transgenic rodent mutation assays. Mutat. Res. 2005, 590:1-280.
10. van Delft J.H., Bergmans A., van Dam F.J., Tates A.D., Howard L., Winton D.J., Baan R.A. Gene-mutation assays in lambda lacZ transgenic mice: comparison of lacZ with endogenous genes in splenocytes and small intestinal epithelium. Mutat. Res. 1998, 415:85-96.
11. Hamed S., LaRue H., Hovington H., Girard J., Jeannotte L., Latulippe E., Fradet Y. Accelerated induction of bladder cancer in patched heterozygous mutant mice. Cancer Res. 2004, 64:1938-1942.
12. Iida K., Itoh K., Kumagai Y., Oyasu R., Hattori K., Kawai K., Shimazui T., Akaza H., Yamamoto M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 2004, 64:6424-6431.
13. Dycaico M.J., Provost G.S., Kretz P.L., Ransom S.L., Moores J.C., Short J.M. The use of shuttle vectors for mutation analysis in transgenic mice and rats. Mutat. Res. 1994, 309:461-478.
14. Jakubczak J.L., Merlino G., French J.E., Muller W.J., Paul B., Adhya S., Garges S. Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage transgene target. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9073-9078.
15. Zimmer D.M., Harbach P.R., Mattes W.B., Aaron C.S. Comparison of mutant frequencies at the transgenic lambda lacl and cll/cl loci in control and ENU-treated big blue mice. Environ. Mol. Mutagen. 1999, 33:249-256.
16. Swiger R.R., Cosentino L., Shima N., Bielas J.H., Cruz-Munoz W., Heddle J.A. The cII locus in the MutaMouse system. Environ. Mol. Mutagen. 1999, 34:201-207.
17. Ogawa K., St John M., Luiza de Oliveira M., Arnold L., Shirai T., Sun T.T., Cohen S.M. Comparison of uroplakin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats and mice. Toxicol. Pathol. 1999, 27:645-651.
18. Ogawa K., Uzvolgyi E., St John M.K., de Oliveira M.L., Arnold L., Cohen S.M. Frequent p53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in B6D2F1 mice. Mol. Carcinog. 1998, 21:70-79.
19. Miyamoto H., Yang Z., Chen Y.T., Ishiguro H., Uemura H., Kubota Y., Nagashima Y., Chang Y.J., Hu Y.C., Tsai M.Y., Yeh S., Messing E.M., Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. J. Natl. Cancer Inst. 2007, 99:558-568.
20. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
21. Salk J.J., Fox E.J., Loeb L.A. Mutational heterogeneity in human cancers: origin and consequences. Annu. Rev. Pathol. 2010, 5:51-75.
22. Mochizuki M., Suzuki E., Okada M. Structure and metabolic fate of N-nitrosodialkylamines in relation to their organotropic carcinogenicity with special reference to induction of urinary bladder tumors. Yakugaku Zasshi J. Pharm. Soc. Jpn. 1997, 117:884-894.
23. Preussmann R., Stewart B.W. N-nitroso carcinogens. Chemical Carcinogens 1984, American Chemical Society, Washington, DC, pp. 643-828.
24. Rothman N., Garcia-Closas M., Chatterjee N., Malats N., Wu X., Figueroa J.D., Real F.X., Van Den Berg D., Matullo G., Baris D., Thun M., Kiemeney L.A., Vineis P., De Vivo I., Albanes D., Purdue M.P., Rafnar T., Hildebrandt M.A., Kiltie A.E., Cussenot O., Golka K., Kumar R., Taylor J.A., Mayordomo J.I., Jacobs K.B., Kogevinas M., Hutchinson A., Wang Z., Fu Y.P., Prokunina-Olsson L., Burdett L., Yeager M., Wheeler W., Tardon A., Serra C., Carrato A., Garcia-Closas R., Lloreta J., Johnson A., Schwenn M., Karagas M.R., Schned A., Andriole G., Grubb R., Black A., Jacobs E.J., Diver W.R., Gapstur S.M., Weinstein S.J., Virtamo J., Cortessis V.K., Gago-Dominguez M., Pike M.C., Stern M.C., Yuan J.M., Hunter D.J., McGrath M., Dinney C.P., Czerniak B., Chen M., Yang H., Vermeulen S.H., Aben K.K., Witjes J.A., Makkinje R.R., Sulem P., Besenbacher S., Stefansson K., Riboli E., Brennan P., Panico S., Navarro C., Allen N.E., Bueno-de-Mesquita H.B., Trichopoulos D., Caporaso N., Landi M.T., Canzian F., Ljungberg B., Tjonneland A., Clavel-Chapelon F., Bishop D.T., Teo M.T., Knowles M.A., Guarrera S., Polidoro S., Ricceri F., Sacerdote C., Allione A., Cancel-Tassin G., Selinski S., Hengstler J.G., Dietrich H., Fletcher T., Rudnai P., Gurzau E., Koppova K., Bolick S.C., Godfrey A., Xu Z., Sanz-Velez J.I., Sanchez D.G.-P.M.M., Valdivia G., Porru S., Benhamou S., Hoover R.N., Fraumeni J.F., Silverman D.T., Chanock S.J. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 2010, 42:978-984.
25. Miyamoto H., Yang Z., Chen Y.T., Ishiguro H., Uemura H., Kubota Y., Nagashima Y., Chang Y.J., Hu Y.C., Tsai M.Y., Yeh S., Messing E.M., Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. J. Natl. Cancer Inst. 2007, 99:558-568.
26. Cohen S.M. Urinary bladder carcinogenesis. Toxicol. Pathol. 1998, 26:121-127.
27. Cohen S.M. Comparative pathology of proliferative lesions of the urinary bladder. Toxicol. Pathol. 2002, 30:663-671.
28. Oyasu R. Epithelial tumours of the lower urinary tract in humans and rodents. Food Chem. Toxicol. 1995, 33:747-755.